Biora Therapeutics
PublicBiora Therapeutics is now publicly traded
The data on this page reflects Biora Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 19, 2020
Last Round
Bankruptcy
Feb 19, 2025
Total Funding Raised
$512.03M
Company Overview
Biora Therapeutics (NAS: BIOR) is a biotechnology company focused on developing innovative oral biotherapeutics that enhance therapeutic delivery for gastrointestinal diseases and provide needle-free, oral alternatives for systemic biotherapeutics.
Sector
Healthcare
AI Layer
Non-AI
Keywords
Biora Therapeutics Comparables
Compare Biora Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hefei Tianhui Biotechnology Co., Ltd. | 61% | |
| Imagine Pharma | 56% | |
| GAT Biosciences S.L. | 56% |
Biora Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Bankruptcy | Feb 19, 2025 | ||||
| Follow-on Offering | Oct 29, 2024 | ||||
| Debt | Aug 12, 2024 | ||||
| Follow-on Offering | Apr 3, 2024 | ||||
| Follow-on Offering | Aug 19, 2021 | ||||
Private Placement | Jun 10, 2021 |
Biora Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| H.C. Wainwright & Co. | Follow-on Offering |
| Davidson Kempner Capital Management | Bankruptcy |
| Wells Fargo Securities, LLC | Follow-on Offering, IPO |
| Athyrium Capital Management | Convertible Debt, Series A, Series B |
| Context Capital Management | Bankruptcy |
| Highbridge Capital Management | Bankruptcy |
Biora Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access